Perbandingan Luaran Klinis Favipiravir dan Remdesivir pada Pasien Covid-19 Derajat Sedang di RS Akademik UGM Yogyakarta
Hadiatussalamah Hadiatussalamah(1), Tri Murti Andayani(2*), Ika Puspita Sari(3)
(1) Magister Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(2) Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(3) Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(*) Corresponding Author
Abstract
Research on effective antivirals for COVID-19 is still ongoing. Favipiravir and remdesivir are antivirals that have been recommended in Indonesia. This study aimed to compare the clinical outcomes of favipiravir and remdesivir in moderate COVID-19 patients. This research is a retrospective cohort study conducted at the UGM Academic Hospital Yogyakarta using electronic medical records of moderate COVID-19 who were hospitalized from June 2021 to March 2022. Each therapy group consisted of 88 subjects. Clinical outcomes in the form of improved and not-improved conditions were assessed using a 7-point ordinal scale of progressivity and recovery of COVID-19 from WHO. Chi-square analysis and multiple logistic regression were performed to determine the relationship between the research variables. The highest percentage of research subjects were aged 18 – 59 years (70,5%), male (53,4%), and not obese (64,2%). The most common comorbidities were diabetes mellitus (33%) and hypertension (30%). The favipiravir group had a better clinical outcome than remdesivir. The proportion of patients improving in the favipiravir group was 50,0% and 35,3% in the remdesivir group (p-value=0,048). There was no significant difference in the number of adverse events between both study groups (p-value > 0,05). The most common adverse drug events were nausea (35,2%), vomiting (14,2%), and heartburn (11,4%).
Keywords
Full Text:
PDFReferences
- WHO Coronavirus (COVID-19) Dashboard. Accessed March 3, 2023. https://covid19.who.int
- Vegivinti CTR, Evanson KW, Lyons H, et al. Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials. BMC Infect Dis. 2022;22:107. doi:10.1186/s12879-022-07068-0
- Angamo MT, Mohammed MA, Peterson GM. Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis. Infection. 2022;50(1):27-41. doi:10.1007/s15010-021-01671-0
- Burhan E, Susanto AD, Nasution SA, et al. Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia. Published online 2022:176.
- Damayanti H, Sajinadiyasa IGK, Risni HW, Sauriasari R. The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia. Kesmas: Jurnal Kesehatan Masyarakat Nasional (National Public Health Journal). 2021;16(4). doi:10.21109/kesmas.v16i4.5433
- Satriyani N, Rahmawati F, Andayani TM. Perbandingan Angka Kematian Terapi Antiviral Favipiravir dan Remdesivir pada Pasien COVID-19 Di RSUP Dr. Sardjito Yogyakarta. JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice). 2023;12(4):223-233. doi:10.22146/jmpf.77288
- Lemeshow S, World Health Organization, eds. Adequacy of Sample Size in Health Studies. Published on behalf of the World Health Organization by Wiley ; Distributed in the U.S.A., Canada, and Japan by Liss; 1990.
- Priya S, Selva Meena M, Sangumani J, Rathinam P, Brinda Priyadharshini C, Vijay Anand V. “Factors influencing the outcome of COVID-19 patients admitted in a tertiary care hospital, Madurai.- a cross-sectional study.” Clin Epidemiol Glob Health. 2021;10:100705. doi:10.1016/j.cegh.2021.100705
- CDC. Cases, Data, and Surveillance. Centers for Disease Control and Prevention. Published February 11, 2020. Accessed April 2, 2023. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html
- Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. doi:10.1001/jama.2020.1585
- Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-1581. doi:10.1001/jama.2020.5394
- Pradhan A, Olsson PE. Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biol Sex Differ. 2020;11:53. doi:10.1186/s13293-020-00330-7
- Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020;383(19):1827-1837. doi:10.1056/NEJMoa2015301
- Udwadia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021;103:62-71. doi:10.1016/j.ijid.2020.11.142
- Shinkai M, Tsushima K, Tanaka S, et al. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. Infect Dis Ther. 2021;10(4):2489-2509. doi:10.1007/s40121-021-00517-4
- WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497-511. doi:10.1056/NEJMoa2023184
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-1578. doi:10.1016/S0140-6736(20)31022-9
- Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, et al. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19. Ann Intern Med. Published online July 13, 2021:M21-0653. doi:10.7326/M21-0653
- Mahajan L, Singh AP, Gifty. Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study. Indian J Anaesth. 2021;65(Suppl 1):S41-S46. doi:10.4103/ija.IJA_149_21
- Dahlan MS. Analisis Multivariat Regresi Logistik. 2nd ed. PT Epidemiologi Indonesia; 2012.
- Zaki N, Alashwal H, Ibrahim S. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review. Diabetes Metab Syndr. 2020;14(5):1133-1142. doi:10.1016/j.dsx.2020.07.005
- Zhu L, She ZG, Cheng X, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020;31(6):1068-1077.e3. doi:10.1016/j.cmet.2020.04.021
- Li G, Chen Z, Lv Z, Li H, Chang D, Lu J. Diabetes Mellitus and COVID-19: Associations and Possible Mechanisms. Kin T, ed. International Journal of Endocrinology. 2021;2021:1-10. doi:10.1155/2021/7394378
- Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol. 2020;52(6):1193-1194. doi:10.1007/s11255-020-02451-9
- Marra F, Smolders EJ, El-Sherif O, et al. Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. Drugs R D. 2021;21(1):9-27. doi:10.1007/s40268-020-00333-0
- Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action. Br J Haematol. 2020;189(5):846-847. doi:10.1111/bjh.16727
- Duo H, Li Y, Sun Y, et al. Effect of therapeutic versus prophylactic anticoagulation therapy on clinical outcomes in COVID-19 patients: a systematic review with an updated meta-analysis. Thrombosis Journal. 2022;20(1):47. doi:10.1186/s12959-022-00408-9
DOI: https://doi.org/10.22146/jmpf.84815
Article Metrics
Abstract views : 664 | views : 722Refbacks
- There are currently no refbacks.
Copyright (c) 2023 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.